Longevity RX: The Evidence-Based Protocol for Living Longer and Healthier

What Does "Longevity RX" Actually Mean?

A longevity prescription is a personalized, physician-supervised plan that targets the biological mechanisms of aging using interventions with measurable endpoints. It is not a supplement stack ordered off the internet. The plan integrates four domains: metabolic health, cardiovascular fitness, hormonal status, and cellular resilience. Each domain has quantifiable biomarkers and evidence-backed interventions that can be adjusted over time.

The distinction between lifespan and healthspan matters here. Lifespan is total years alive. Healthspan is years lived free from disabling disease or significant functional decline. Most people conflate the two, but a 90-year-old spending a decade bedridden has a long lifespan and a short healthspan. The goal of a proper longevity protocol is compressing morbidity, a concept first formalized by Dr. James Fries in a 1980 New England Journal of Medicine paper and supported by subsequent cohort data [1].

A well-designed protocol starts with a baseline panel of biomarkers, assigns priority interventions based on your individual gaps, and re-tests at defined intervals. The sections below walk through each domain in clinical order of impact.

VO2 Max Is the Single Strongest Predictor of Longevity

Among all measurable fitness markers, VO2 max carries the highest predictive value for all-cause and cardiovascular mortality. A 2018 JAMA Network Open analysis (N=122,007) found that low cardiorespiratory fitness carried a mortality hazard ratio of 5.04 compared with elite fitness, exceeding the risk associated with smoking, hypertension, diabetes, and end-stage renal disease [2]. Moving from the bottom quartile to the second quartile alone reduced mortality by approximately 45%.

VO2 max declines roughly 10% per decade after age 30 without intervention. The good news is that it responds strongly to training. The AHA recommends 150-300 minutes of moderate-intensity or 75-150 minutes of vigorous aerobic activity per week as a minimum [3]. Research published in Circulation shows that adding two sessions per week of high-intensity interval training (HIIT) on top of a moderate base can raise VO2 max by 10-15% within 12 weeks in previously sedentary adults [4].

Practical VO2 max testing options include a formal maximal exercise test in a cardiology or sports medicine clinic, or a validated sub-maximal field test such as the Rockport 1-mile walk. A target VO2 max above the 75th percentile for your age and sex provides a meaningful mortality buffer, according to the same JAMA analysis.

Resistance Training and Muscle Mass: The Underrated Longevity Drug

Cardiovascular fitness gets most of the attention, but skeletal muscle mass may be equally important. A 2014 analysis in the American Journal of Medicine (N=3,659 adults) found that each 10% increase in muscle mass index was associated with an 11% lower all-cause mortality risk, independent of fat mass [5]. Sarcopenia (muscle loss with aging) predicts falls, metabolic dysfunction, and early death.

Resistance training two to three days per week preserves muscle mass and improves insulin sensitivity. A Cochrane systematic review confirmed that progressive resistance training significantly improves physical function and reduces disability in older adults [6]. The key word is progressive: the load must increase over time to drive adaptation.

Protein intake is the dietary lever most directly tied to muscle preservation. A position statement from the International Society of Sports Nutrition recommends 1.6-2.2 g of protein per kilogram of body weight per day for individuals seeking to maintain or build muscle mass [7]. After age 50, leucine-rich sources (whey, eggs, beef, legumes combined with grains) become especially relevant because of age-related anabolic resistance.

Sleep: The Non-Negotiable Biological Reset

Sleep is not a passive state. It is when the glymphatic system clears amyloid-beta and tau from the brain, when growth hormone pulses, and when cortisol resets. A meta-analysis of 16 prospective studies (N=1.3 million participants) published in Sleep found that sleeping <6 hours per night was associated with a 12% increased all-cause mortality risk, while sleeping <5 hours raised cardiovascular mortality risk by approximately 2-fold [8].

The National Sleep Foundation and the American Academy of Sleep Medicine both recommend 7-9 hours per night for adults [9]. Achieving that target requires consistent sleep and wake times, a bedroom temperature between 65-68°F, and limiting blue-light exposure for 60-90 minutes before bed.

For patients with suspected obstructive sleep apnea, formal polysomnography or a validated home sleep test is appropriate. Untreated sleep apnea raises the risk of atrial fibrillation, hypertension, and type 2 diabetes and should be addressed before adding any other longevity intervention.

Metabolic Health: Insulin Resistance Is the Silent Accelerant of Aging

Chronic hyperinsulinemia and insulin resistance accelerate nearly every aging pathway examined, from mTOR dysregulation to mitochondrial dysfunction to systemic inflammation. The CDC estimates that 96 million American adults, roughly 38% of the adult population, have prediabetes [10]. Most do not know it.

The relevant biomarkers are fasting glucose, fasting insulin (HOMA-IR calculation), HbA1c, and triglycerides. A fasting insulin above 10 µIU/mL suggests early insulin resistance even when fasting glucose is still normal [11]. HOMA-IR above 2.0 is a clinically useful threshold for initiating dietary and lifestyle intervention.

Dietary interventions shown in randomized trials to improve insulin sensitivity include time-restricted eating (16:8 protocols), low-glycemic Mediterranean-style diets, and protein-prioritized dietary patterns. A 2-year randomized trial (CALERIE-2, N=218) showed that 25% caloric restriction improved insulin sensitivity, blood pressure, and inflammatory markers without adverse effects on bone density or lean mass at the tested caloric restriction level [12].

GLP-1 Receptor Agonists: Beyond Weight Loss

GLP-1 receptor agonists were initially approved for type 2 diabetes but their profile of effects extends well beyond glucose control. The SELECT trial (N=17,604 overweight or obese adults without diabetes) showed that semaglutide 2.4 mg subcutaneously once weekly reduced major adverse cardiovascular events (MACE) by 20% over a median follow-up of 34 months compared with placebo [13]. This was the first cardiovascular outcomes trial to show a MACE benefit in a population without pre-existing diabetes.

In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [14]. Body weight reduction of this magnitude meaningfully reduces hepatic steatosis, sleep apnea severity, osteoarthritic joint load, and systemic inflammation, each of which contributes independently to mortality risk.

Ongoing research is examining GLP-1 agonists in Alzheimer's disease prevention. The EVOKE trial is assessing oral semaglutide in early Alzheimer's disease, and observational data from the FDA Adverse Event Reporting System suggest a lower-than-expected dementia signal among GLP-1 users. These data are preliminary but warrant attention.

Current FDA-approved GLP-1 options relevant to a longevity protocol include semaglutide (Ozempic for diabetes, Wegovy for weight management), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro for diabetes, Zepbound for weight management) [15].

Hormone Optimization: Testosterone, Estrogen, and DHEA

Hormonal decline is not simply an inconvenience of aging. It is a measurable contributor to metabolic disease, cardiovascular risk, cognitive decline, and loss of muscle mass.

Testosterone in men. A 20-year prospective study (N=794 men, mean follow-up 20 years) published in European Heart Journal found that men in the lowest testosterone quartile had a 35% higher all-cause mortality risk compared with men in the highest quartile [16]. The FDA has approved testosterone replacement therapy for hypogonadism, defined as a total testosterone below 300 ng/dL accompanied by symptoms [17]. The TRAVERSE trial (N=5,246 hypogonadal men with elevated cardiovascular risk) found that testosterone replacement was non-inferior to placebo for MACE over a mean 33-month follow-up, providing important safety data for this population [18].

Estrogen in women. The Women's Health Initiative re-analyses and the KEEPS trial data indicate that timing matters for estrogen's cardiovascular effects. Initiating hormone therapy within 10 years of menopause or before age 60 is associated with reduced cardiovascular risk, a finding sometimes called the "timing hypothesis" supported by the Endocrine Society's 2022 position statement [19]. The menopause.org position statement from the Menopause Society (formerly NAMS) states: "For most healthy symptomatic women who are within 10 years of menopause onset or are younger than 60 years, the benefits of hormone therapy outweigh the risks" [20].

DHEA-S. Dehydroepiandrosterone sulfate declines approximately 80% from peak levels by age 70. Observational data consistently associate low DHEA-S with higher cardiovascular and all-cause mortality, though randomized trial evidence for supplementation remains mixed [21]. DHEA 25-50 mg/day is a low-risk adjunct that some clinicians include when levels fall below the lower quartile for age.

Key Biomarkers to Track: The Longevity Panel

No protocol survives without measurement. The following biomarkers form a defensible minimum longevity panel, based on their predictive value for mortality and their responsiveness to intervention.

Apolipoprotein B (ApoB). ApoB directly counts atherogenic lipoprotein particles and outperforms LDL-cholesterol for cardiovascular risk prediction. Target: <80 mg/dL for high-risk individuals, <100 mg/dL for moderate risk, per ACC/AHA guidance [22].

High-sensitivity CRP (hsCRP). A marker of systemic inflammation and independent cardiovascular risk predictor. The JUPITER trial (N=17,802) showed that rosuvastatin 20 mg reduced cardiovascular events by 44% in people with normal LDL but elevated hsCRP (>2 mg/L) [23]. Target: <1 mg/L.

Fasting insulin and HOMA-IR. Discussed above. Order alongside fasting glucose for a complete picture.

HbA1c. Reflects 3-month average glucose. Target for non-diabetic longevity optimization: <5.7%.

Ferritin. Both low ferritin (fatigue, cognitive impairment, poor athletic performance) and high ferritin (hemochromatosis, chronic inflammation) carry mortality risk. Optimal range is approximately 50-150 ng/mL for most adults [24].

Testosterone (total and free), SHBG, LH, FSH. Essential for any adult over 35 experiencing fatigue, body composition changes, low libido, or mood disruption.

IGF-1. Reflects growth hormone axis activity. Both very low and very high IGF-1 associate with elevated mortality; mid-normal range is the target.

The HealthRX.com Longevity Panel groups these markers into three tiers: Tier 1 tests ordered at baseline and every 12 months; Tier 2 tests added if Tier 1 reveals an abnormality; Tier 3 advanced tests (e.g., CIMT, coronary artery calcium score, continuous glucose monitoring) reserved for patients with multiple Tier 1 abnormalities or strong family history of premature cardiovascular disease.

Diet: What the Longest-Lived Populations Actually Eat

Blue Zone populations (Okinawa, Sardinia, Nicoya, Ikaria, Loma Linda) share dietary patterns, not individual superfoods. A 2021 systematic review in Advances in Nutrition found that Mediterranean-style and plant-predominant dietary patterns were associated with a 20-30% reduction in all-cause mortality compared with Western dietary patterns [25]. No single supplement or food product replicates this effect.

The practical dietary principles supported by that evidence base:

Eat protein at 1.6-2.2 g/kg/day, distributed across at least three meals to saturate muscle protein synthesis signaling. Prioritize minimally processed whole foods. Keep added sugar below 25 g/day (the American Heart Association's recommended limit) [26]. Consume omega-3 fatty acids through fatty fish two to three times per week or a quality fish oil providing at least 1 g EPA+DHA daily, given evidence from the REDUCE-IT trial (N=8,179) showing a 25% reduction in MACE with 4 g icosapentaenoic acid (Vascepa) daily [27].

Alcohol warrants a direct statement. A 2018 Lancet analysis (N=599,912 current drinkers) found no safe level of alcohol consumption for overall health, with risk beginning above 100 g of pure alcohol per week, or roughly 5-6 standard drinks [28]. Light drinking does not extend life.

Supplements With Meaningful Evidence

Most supplements sold under longevity branding have no randomized controlled trial data in humans. The short list with actual evidence:

Creatine monohydrate. 3-5 g/day improves muscle power, bone density, and cognitive performance in older adults. A 2022 meta-analysis in Nutrients (N=1,374 participants across 22 RCTs) found significant improvements in lean mass and functional performance [29].

Vitamin D3 with K2. Vitamin D deficiency (<20 ng/mL) is associated with higher all-cause mortality in multiple cohort studies. The VITAL trial (N=25,871) found that vitamin D3 2000 IU/day reduced cancer mortality by 17% over a 5-year follow-up [30]. Target serum 25(OH)D: 40-60 ng/mL.

Magnesium glycinate or malate. Magnesium participates in over 300 enzymatic reactions. Approximately 48% of Americans consume less than the recommended dietary allowance. A meta-analysis in BMC Medicine (N=1 million participants) found that each 100 mg/day increase in dietary magnesium was associated with a 22% lower risk of heart failure and a 7% lower risk of type 2 diabetes [31].

Omega-3 (EPA+DHA). Addressed above under diet. At least 1 g combined EPA+DHA daily from fish oil supports a longevity protocol when dietary intake is insufficient.

Metformin and rapamycin are under active investigation in aging trials (TAME trial for metformin; multiple rapamycin pilot studies), but neither carries current FDA approval for longevity indications outside their licensed uses [32]. Prescribing them off-label for aging prevention is a clinical decision requiring individual risk-benefit analysis.

Stress, Cortisol, and the Telomere Connection

Chronic psychological stress activates the HPA axis, raising cortisol chronically. Sustained cortisol elevation accelerates telomere shortening, impairs immune function, promotes visceral fat deposition, and disrupts sleep architecture. A landmark study by Epel and colleagues published in PNAS (N=58 women) showed that perceived psychological stress was directly associated with shorter telomere length, lower telomerase activity, and higher oxidative stress [33].

Interventions with RCT-level evidence for reducing cortisol include structured aerobic exercise, mindfulness-based stress reduction (MBSR), and adequate sleep. MBSR was shown in a meta-analysis of 39 RCTs to produce significant reductions in perceived stress and cortisol across diverse adult populations [34]. Eight weeks at 45 minutes per day is the standard MBSR protocol studied in most trials.

Putting It Together: A Starting Longevity Protocol

A reasonable first-pass longevity protocol for a healthy 40-year-old with no major comorbidities looks like this:

Order the Tier 1 biomarker panel at baseline. Address any abnormalities in ApoB, fasting insulin, testosterone, or vitamin D before adding complexity. Achieve 150 minutes per week of Zone 2 cardio (a conversational pace maintaining roughly 60-70% of maximum heart rate) plus two sessions of progressive resistance training. Hit a protein target of 1.6 g/kg/day. Sleep 7-9 hours per night with consistent timing. Take vitamin D3 2000 IU and magnesium glycinate 300-400 mg daily. Retest the panel at 12 months.

For patients with a BMI above 30, cardiovascular risk factors, or significant insulin resistance, a GLP-1 receptor agonist consultation is appropriate given SELECT and STEP-1 data. For men with total testosterone below 300 ng/dL with symptoms, a testosterone evaluation and consideration of TRT per TRAVERSE safety data is warranted. For peri- or postmenopausal women within 10 years of menopause onset, HRT eligibility assessment per Menopause Society guidelines is appropriate.

Start with the fundamentals. A VO2 max in the top quartile for your age buys more life-years than any single pharmaceutical. The 2018 JAMA Network Open data showing a 5x mortality hazard for low cardiorespiratory fitness remains the most important number in longevity medicine [2].